Bispecific antibodies: advancing precision oncology
- Author(s)
- Herrera, M; Pretelli, G; Desai, J; Garralda, E; Siu, LL; Steiner, TM; Au, L;
- Details
- Publication Year 2024-10,Volume 10,Issue #10,Page 893-919
- Journal Title
- Trends in Cancer
- Publication Type
- Review
- Abstract
- Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets and structure (or format), which can be manipulated to create variable and novel functionalities, including linking immune cells with tumor cells, or dual signaling pathway blockade. Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to these agents are understudied and the management of toxicities remains challenging. Herein, we review the principles in bsAb engineering, current understanding of mechanisms of action and resistance, data for clinical application, and provide a perspective on ongoing challenges and future developments in this field.
- Publisher
- Cell Press
- Keywords
- *Antibodies, Bispecific/therapeutic use/pharmacology/immunology; Humans; *Precision Medicine/methods; *Neoplasms/immunology/therapy/drug therapy; Drug Resistance, Neoplasm/immunology/drug effects; Animals; Antineoplastic Agents, Immunological/therapeutic use/pharmacology; Molecular Targeted Therapy/methods; T cell engagers; antibody engineering; bispecific antibodies; dual-targeted therapy; immunotherapy
- Department(s)
- Medical Oncology; Laboratory Research
- Publisher's Version
- https://doi.org/10.1016/j.trecan.2024.07.002
- Open Access at Publisher's Site
https://doi.org/10.1016/j.trecan.2024.07.002- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-23 03:11:51
Last Modified: 2024-10-23 03:12:06